Lymph node metastases showed stable PSMA uptake (median SUVmax) after treatment (7.8 vs. 7.7, p = 0.77), while uptake by bone (6.4 vs. 12.4, p = 0.03) and lung metastases (4.5 vs. 8.1, p = 0.004) increased significantly. The gene discussed is FOLH1; the disease is metastatic malignant neoplasm in the lymph nodes.